Phase II Trial of Continuation Therapy in Advanced NSCLC
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a single-arm phase II study of continuation immunotherapy with pembrolizumab
following initial benefit (CR, PR, or SD ≥ 3 months) with a PD-1 or PD-L1 inhibitor.
Phase:
Phase 2
Details
Lead Sponsor:
Greg Durm Greg Durm, MD
Collaborators:
Big Ten Cancer Research Consortium Merck Sharp & Dohme Corp.